The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

beta-Hydroxytyrosine     2-amino-3-(3,4- dihydroxyphenyl)propanoic acid

Synonyms: DL-DOPA, DL -Dopa, SureCN24360, AGN-PC-006IKJ, CHEMBL351042, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Levopa


Psychiatry related information on Levopa


High impact information on Levopa


Chemical compound and disease context of Levopa


Biological context of Levopa


Anatomical context of Levopa


Associations of Levopa with other chemical compounds


Gene context of Levopa


Analytical, diagnostic and therapeutic context of Levopa


  1. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. Nutt, J.G., Woodward, W.R., Hammerstad, J.P., Carter, J.H., Anderson, J.L. N. Engl. J. Med. (1984) [Pubmed]
  2. Facilitation of levodopa-induced dyskinesias by dietary carbohydrates. Wurtman, R., Caballero, B., Salzman, E. N. Engl. J. Med. (1988) [Pubmed]
  3. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., Benabid, A.L. N. Engl. J. Med. (1998) [Pubmed]
  4. Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. Rajfer, S.I., Anton, A.H., Rossen, J.D., Goldberg, L.I. N. Engl. J. Med. (1984) [Pubmed]
  5. Levodopa provocative test for Huntington's disease. Fahn, S. N. Engl. J. Med. (1980) [Pubmed]
  6. Letter: Narcolepsy: REM sleep suppression by L-dopa. Gilbert, J.C., Willer, J.C., Bernheim-Chaltelain, C., Ecoffet, M., Jaillon, P. N. Engl. J. Med. (1976) [Pubmed]
  7. Etiology and pathogenesis of Parkinson's disease. Olanow, C.W., Tatton, W.G. Annu. Rev. Neurosci. (1999) [Pubmed]
  8. Levodopa in restless legs. von Scheele, C. Lancet (1986) [Pubmed]
  9. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Meco, G., Alessandria, A., Bonifati, V., Giustini, P. Lancet (1994) [Pubmed]
  10. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.Q., Eidelberg, D., Fahn, S. N. Engl. J. Med. (2001) [Pubmed]
  11. Ropinirole as compared with levodopa in Parkinson's disease. Yamamoto, T. N. Engl. J. Med. (2000) [Pubmed]
  12. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., Lang, A.E. N. Engl. J. Med. (2000) [Pubmed]
  13. False-negative results with levodopa for early detection of Huntington's disease. Myers, R.H., Growdon, J.H., Bird, E.D., Feldman, R.G., Martin, J.B. N. Engl. J. Med. (1982) [Pubmed]
  14. Treatment of parkinson's disease with bromocriptine. Lieberman, A., Kupersmith, M., Estey, E., Goldstein, M. N. Engl. J. Med. (1976) [Pubmed]
  15. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. Cotzias, G.C., Papavasiliou, P.S., Tolosa, E.S., Mendez, J.S., Bell-Midura, M. N. Engl. J. Med. (1976) [Pubmed]
  16. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. Sternberg, E.M., Van Woert, M.H., Young, S.N., Magnussen, I., Baker, H., Gauthier, S., Osterland, C.K. N. Engl. J. Med. (1980) [Pubmed]
  17. Administration of levodopa for relief of herpes zoster pain. Kernbaum, S., Hauchecorne, J. JAMA (1981) [Pubmed]
  18. Selective transsphenoidal adenomectomy in women with galactorrhea-amenorrhea. Post, K.D., Biller, B.J., Adelman, L.S., Molitch, M.E., Wolpert, S.M., Reichlin, S. JAMA (1979) [Pubmed]
  19. Modulation of peroxidation in murine melanoma by dietary tyrosine-phenylalanine restriction, levodopa methylester chemotherapy, and sodium ascorbate supplementation. Pierson, H.F., Meadows, G.G. J. Natl. Cancer Inst. (1985) [Pubmed]
  20. Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial. Michel, H., Solere, M., Granier, P., Cauvet, G., Bali, J.P., Pons, F., Bellet-Hermann, H. Gastroenterology (1980) [Pubmed]
  21. Effect of L-dopa on course of Parkinson's disease. Curtis, L., Lees, A.J., Stern, G.M., Marmot, M.G. Lancet (1984) [Pubmed]
  22. Human growth hormone response to levodopa. Relation to menopause, depression, and plasma dopa concentration. Sachar, E.J., Altman, N., Gruen, P.H., Glassman, A., Halpern, F.S., Sassin, J. Arch. Gen. Psychiatry (1975) [Pubmed]
  23. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Valente, E.M., Bentivoglio, A.R., Dixon, P.H., Ferraris, A., Ialongo, T., Frontali, M., Albanese, A., Wood , N.W. Am. J. Hum. Genet. (2001) [Pubmed]
  24. Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Zuscik, M.J., Sands, S., Ross, S.A., Waugh, D.J., Gaivin, R.J., Morilak, D., Perez, D.M. Nat. Med. (2000) [Pubmed]
  25. L-Dopa methyl ester: prolongation of survival of neuroblastoma-bearing mice after treatment. Wick, M.M. Science (1978) [Pubmed]
  26. PET studies and motor complications in Parkinson's disease. Brooks, D.J. Trends Neurosci. (2000) [Pubmed]
  27. Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. Johnson, B.E., Battey, J., Linnoila, I., Becker, K.L., Makuch, R.W., Snider, R.H., Carney, D.N., Minna, J.D. J. Clin. Invest. (1986) [Pubmed]
  28. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Fisher, L.J., Jinnah, H.A., Kale, L.C., Higgins, G.A., Gage, F.H. Neuron (1991) [Pubmed]
  29. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Kartzinel, R., TEYCHENNE, P., Gillespie, M.M., Perlow, M., Gielen, A.C., Sadowsky, D.A., Calne, D.B. Lancet (1976) [Pubmed]
  30. Histamine synthesis by intact mast cells from canine fundic mucosa and liver. Beaven, M.A., Soll, A.H., Lewin, K.J. Gastroenterology (1982) [Pubmed]
  31. Quantitative correlation of dopamine-dependent adenylate cyclase with responses to levodopa in various mice. Tang, L.C., Cotzias, G.C. Proc. Natl. Acad. Sci. U.S.A. (1977) [Pubmed]
  32. Single-molecule mechanics of mussel adhesion. Lee, H., Scherer, N.F., Messersmith, P.B. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  33. Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Porrino, L.J., Burns, R.S., Crane, A.M., Palombo, E., Kopin, I.J., Sokoloff, L. Proc. Natl. Acad. Sci. U.S.A. (1987) [Pubmed]
  34. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. de Vries, T.J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter, D.J., van Muijen, G.N. Cancer Res. (1997) [Pubmed]
  35. Transforming growth factor-beta1 inhibits basal melanogenesis in B16/F10 mouse melanoma cells by increasing the rate of degradation of tyrosinase and tyrosinase-related protein-1. Martínez-Esparza, M., Jiménez-Cervantes, C., Beermann, F., Aparicio, P., Lozano, J.A., García-Borrón, J.C. J. Biol. Chem. (1997) [Pubmed]
  36. Melanocyte-specific proteins are aberrantly trafficked in melanocytes of Hermansky-Pudlak syndrome-type 3. Boissy, R.E., Richmond, B., Huizing, M., Helip-Wooley, A., Zhao, Y., Koshoffer, A., Gahl, W.A. Am. J. Pathol. (2005) [Pubmed]
  37. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Bonifati, V., Meco, G. Pharmacol. Ther. (1999) [Pubmed]
  38. Hypothalamic-pituitary function in patients with prolonged coma. Sack, J., Sazbon, L., Lunenfeld, B., Najenson, T. J. Clin. Endocrinol. Metab. (1983) [Pubmed]
  39. Basal ganglia and movement disorders: an update. Chesselet, M.F., Delfs, J.M. Trends Neurosci. (1996) [Pubmed]
  40. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Quinn, N., Marsden, C.D., Parkes, J.D. Lancet (1982) [Pubmed]
  41. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Scheidtmann, K., Fries, W., Müller, F., Koenig, E. Lancet (2001) [Pubmed]
  42. Dopamine agonist monotherapy in Parkinson's disease. Clarke, C.E., Guttman, M. Lancet (2002) [Pubmed]
WikiGenes - Universities